Access to inexpensive sequencing technologies is creating new opportunities in clinical and consumer genomics. From companies that claim to use genetic data to create personalized training programs, to better understanding disease risk, the spectrum of applications is vast and ever-growing.
Companies such as 23andMe, GRAIL, Foundation Medicine, and Helix are challenging established paradigms in drug development, cancer screening and self-awareness. Along the way, they have raised tremendous sums of money and established an enviable list of partners.
Join us as we speak with entrepreneurs and investors in some of the leading players to explore their business models (B2C vs B2B) and how they are handling issues around data management, data privacy and ownership.
Ability Level: All
Session ID: 19823